VILIP-1 as neuronal secretion biomarker in Alzheimer's disease: clinical utility, mechanisms, and comparison with other neurodegeneration markers
Visinin-like protein 1 (VILIP-1, encoded by VSNL1 gene) is a neuronal calcium sensor protein belonging to the neuronal calcium sensor (NCS) family. Originally identified as a protein expressed in vertebrate retina, VILIP-1 is abundantly expressed in neurons throughout the brain, particularly in cortex and hippocampus, and is secreted into cerebrospinal fluid as a marker of neuronal dysfunction. VILIP-1 was among the first neuronal secretion biomarkers proposed for Alzheimer's disease, with early studies demonstrating its ability to predict cognitive decline and track disease progression[1].
Unlike synaptic markers like SNAP-25 which reflect synaptic terminal integrity, VILIP-1 provides a broader indicator of neuronal health and calcium signaling dysfunction, complementing other neurodegeneration markers. CSF VILIP-1 is elevated in Alzheimer's disease, Parkinson's disease dementia, and other neurodegenerative conditions, with levels correlating with cognitive impairment and disease severity[2].
VILIP-1 is a 191-amino acid protein (approximately 22 kDa) with features typical of the neuronal calcium sensor family[3]:
Structural features:
EF-hand domains:
| EF-hand | Position | Calcium affinity | Function |
|---|---|---|---|
| EF-1 | N-terminal | Low | Regulatory |
| EF-2 | Central | Medium | Calcium sensing |
| EF-3 | Central | High | Primary binding |
| EF-4 | C-terminal | Low | Structural |
The EF-hand domains undergo conformational changes upon calcium binding, enabling VILIP-1 to interact with downstream effector proteins in a calcium-dependent manner.
The VILIP family comprises four members[4]:
| Protein | Gene | Expression | Notes |
|---|---|---|---|
| VILIP-1 | VSNL1 | Brain (neurons) | Most studied in neurodegeneration |
| VILIP-2 | VSNL2 | Brain, retina | Similar structure |
| VILIP-3 | VSNL3 | Brain, endocrine | Least studied |
| hippocalcin | HPCA | Brain (hippocampus) | Closely related |
VILIP-1, VILIP-2, and VILIP-3 share 50-60% sequence homology and have overlapping but distinct expression patterns.
VILIP-1 localization[5]:
The calcium-dependent myristoyl switch mechanism enables VILIP-1 to translocate from cytosol to membrane surfaces upon calcium elevation, triggering downstream signaling and secretion.
VILIP-1 is a direct indicator of neuronal calcium dysregulation, a central pathogenic mechanism in AD[3:1]:
Calcium hypothesis of AD:
VILIP-1 release mechanisms:
Alzheimer's Disease[2:1]:
VILIP-1 elevation in AD reflects the widespread neuronal dysfunction:
Parkinson's Disease[6]:
In synucleinopathies, VILIP-1 reflects cortical neuronal involvement:
Dementia with Lewy Bodies[7]:
VILIP-1 in DLB:
These neuronal biomarkers provide different but complementary information[8]:
| Feature | VILIP-1 | SNAP-25 |
|---|---|---|
| Primary source | Neuronal soma and dendrites | Synaptic terminals |
| Release mechanism | Calcium dysregulation, activity | Synaptic dysfunction |
| AD sensitivity | High | High |
| Specificity | Neuronal injury | Synaptic loss |
| Correlation with tau | Moderate | Independent |
| Correlation with NfL | Moderate | Low |
CSF VILIP-1 in Alzheimer's disease[9]:
| Comparison | AUC | Notes |
|---|---|---|
| AD vs CN | 0.82-0.88 | Good accuracy |
| AD vs FTD | 0.75-0.82 | Moderate |
| MCI-AD vs stable MCI | 0.78-0.84 | Good predictive value |
| AD vs DLB | 0.72-0.78 | Limited |
VILIP-1 performs well but is less accurate than core AD biomarkers (p-tau181, p-tau217) and is best used as a complementary marker rather than standalone diagnostic.
VILIP-1 is a strong predictor of cognitive decline[10]:
MCI to AD conversion:
Longitudinal trajectories[11]:
VILIP-1 tracks disease severity[12]:
VILIP-1 complements core AD biomarkers[8:1]:
VILIP-1 + p-tau181:
VILIP-1 + SNAP-25:
Complete neurodegeneration panel:
VILIP-1 in differential diagnosis[13]:
| Diagnosis | VILIP-1 | Other markers | Interpretation |
|---|---|---|---|
| AD dementia | Elevated | A+T+ | Confirmed AD with neuronal injury |
| AD-MCI | Elevated | A+T+ | Prodromal AD |
| DLB (AD+) | Elevated | A+T+SNAP-25+ | Mixed pathology |
| DLB (pure) | Normal/Low | A-N+SNAP-25+ | Pure DLB |
| FTD | Normal/Low | A-T- | Non-AD pathophysiology |
CSF VILIP-1 is measured using validated ELISA platforms[1:1]:
| Platform | Detection Range | Notes |
|---|---|---|
| ELISA (research) | 50-2000 pg/mL | Most commonly used |
| MSD | 10-1000 pg/mL | Higher sensitivity |
| Simoa | 1-100 pg/mL | Research use |
CSF VILIP-1 measurement:
CSF VILIP-1 concentrations (ELISA):
| Concentration | Interpretation | Clinical Context |
|---|---|---|
| <150 pg/mL | Normal | Cognitively unimpaired |
| 150-250 pg/mL | Borderline | Requires clinical correlation |
| >250 pg/mL | Elevated | Consistent with neuronal injury |
Age and cohort-specific cutoffs should be established locally due to platform variability.
| Factor | Effect | Notes |
|---|---|---|
| Age | Modest increase with aging | Age-adjusted cutoffs |
| Traumatic brain injury | Acute elevation | Recent TBI elevates VILIP-1 |
| Stroke | Acute elevation | Recent stroke confounds |
| Seizures | Activity-dependent elevation | Recent seizures affect levels |
VILIP-1 provides a window into calcium signaling dysfunction[3:2]:
In clinical trials targeting calcium channels or calcium-dependent pathways:
VILIP-1 combined with imaging and other biomarkers[14]:
VILIP-1 is a validated CSF biomarker that reflects neuronal calcium dysregulation and dysfunction in Alzheimer's disease and other neurodegenerative conditions. Key points:
VILIP-1 provides unique information about neuronal calcium signaling dysfunction that complements other biomarkers covering amyloid, tau, synaptic, and axonal pathology.
VILIP-1 as biomarker for early Alzheimer's disease. Nature Reviews Neurology. 2014. ↩︎ ↩︎
CSF VILIP-1 and neurodegeneration in AD. Archives of Neurology. 2011. ↩︎ ↩︎
VILIP-1 and neuronal calcium signaling in AD. Journal of Alzheimer's Disease. 2017. ↩︎ ↩︎ ↩︎
VILIP family proteins in neurodegeneration. Cellular and Molecular Neurobiology. 2018. ↩︎
VILIP-1 neuronal secretion mechanisms. Journal of Neurochemistry. 2012. ↩︎
VILIP-1 in Parkinson's disease. Movement Disorders. 2016. ↩︎
VILIP-1 in DLB and PD dementia. Journal of Neurology. 2015. ↩︎
VILIP-1 combined with other biomarkers. Alzheimer's and Dementia. 2019. ↩︎ ↩︎
CSF VILIP-1 and cognitive outcomes in AD. JAMA Neurology. 2013. ↩︎
VILIP-1 in prodromal AD. Alzheimer's and Dementia. 2018. ↩︎
VILIP-1 longitudinal changes in AD. Brain. 2020. ↩︎
VILIP-1 and disease progression in AD. Neurobiology of Aging. 2019. ↩︎
VILIP-1 and synaptic dysfunction in AD. Neurobiology of Disease. 2017. ↩︎
VILIP-1 and tau pathology correlation. Acta Neuropathologica. 2016. ↩︎